Targeting high density lipoproteins in the prevention of cardiovascular disease?

Current Cardiology Reports

Volumn 14, Issue 6, 2012, Pages 684-691

  Larach, Daniel B ^a   DeGoma, Emil M ^a   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anacetrapib; ApoA I; Cardiovascular disease; CETP; Cholesteryl ester transfer protein; Dalcetrapib; Evacetrapib; GPR109A; HDL; Lipids; Liver X receptor; MiR 33; Niacin; Recombinant HDL; Reverse cholesterol transport; RVX 208; Torcetrapib

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; AZ 876; CARDIOVASCULAR AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; CSL 112; DALCETRAPIB; ETC 216; EVACETRAPIB; EZETIMIBE PLUS SIMVASTATIN; GW 6340; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA 33; NICOTINIC ACID; PLACEBO; RVX 208; SIMVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; NIACIN;

EID: 84870547907     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0317-3     Document Type: Article

References (86)

1. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16.
2. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15.
3. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199-211.
4. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67.
5. Roche provides update on Phase III study of dalcetrapib. Roche. 2012. http://www.roche.com/media/media-releases/med-cor-2012-05-07.htm. Accessed 11 Sept 2012.
6. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572-80.
7. Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010;105:487-94.
8. Bays HE, Shah A, Lin J, McCrary Sisk C, Paolini JF, Maccubbin D. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol. 2010;4(6):515-21.
9. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extended-release niacin/laropiprant plus statin vs doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2010;64:727-38.
10. Bays HE, Shah A, Lin J, Sisk CM, Dong Q, Maccubbin D. Consistency of extended-release niacin/laropiprant effects on Lp (a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups. Am J Cardiovasc Drugs. 2012;12:197-206.
11. Dunbar RL, Gelfand JM. Seeing red: flushing out instigators of niacin-associated skin toxicity. J Clin Invest. 2010;120:2651-5.
12. Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest. 2010;120:2910-9.
13. Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012;32:582-8
14. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant vs gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104:74-81.
15. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nature Medicine. 2003;9:352-5.
16. Lauring B, Taggart AK, Tata JR, et al. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Science Translational Med, 2012;4(148).
17. Lai E, Waters G, Tata J, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol. 2008;2:375-83.
18. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest. 2011;121(3):1163-73
19. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-92.
20. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-55.
21. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-7.
22. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721-6.
23. Duggal JK, Singh M, Attri N, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010;15:158-66.
24. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353-61.
25. Brinton EA. Search and rescue for hypotheses surviving AIMHIGH, the niacin therapy earthquake: still problematic after the primary publication. J Clin Lipidol. 2012;6:312-7.
26. National Heart, Lung, and Blood Institute; Abbott. Niacin plus statin to prevent vascular events. In: ClinicalTrials.gov. National Library of Medicine. 2011. http://www.clinicaltrials.gov/ct2/show/NCT00120289. Accessed 11 Sept 2012.
27. University of Oxford; Merck. Treatment of HDL to reduce the incidence of vascular events HPS2-THRIVE. In: ClinicalTrials.gov. National Library of Medicine. 2010. http://www.clinicaltrials.gov/ct2/show/NCT00461630. Accessed 11 Sept 2012.
28. Neeli H, Rader DJ. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiol Clin. 2008;26: 537-46.
29. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-15.
30. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-22.
31. Rader DJ. Illuminating HDL-is it still a viable therapeutic target? N Engl J Med. 2007;357:2180-3.
32. Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol. 2009;104(10 Suppl):10E-5E.
33. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002;105(18):2159-65.
34. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol. 2005;95(9):1085-8.
35. Stein EA, Roth EM, Rhyne JM, Burgess T, Kallend D, Robinson JG. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J. 2010;31:480-8.
36. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomized clinical trial. Lancet. 2011;378:1547-59.
37. Luscher TF, Taddei S, Kaski JC, et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33:857-65.
38. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res. 2010;51:2739-52.
39. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: 2 double-blind, randomized placebocontrolled phase I studies. Lancet. 2007;370:1907-14.
40. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157(e352):352-60.
41. Dansky HM, Bloomfield D, Gibbons P, et al. Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. Am Heart J. 2011;162:708-16.
42. Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res. 2012;53:540-7.
43. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30:1430-8.
44. Castro-Perez J, Briand F, Gagen K, et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res. 2011;52:1965-73.
45. Cannon CP, Dansky HM, Davidson M, et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158(e513):513-19.
46. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Eng J Med. 2010;363:2406-15.
47. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA:J Am Med Assoc. 2011;306:2099-109.
48. Nicholls SJ. Evacetrapib. Current Cardiol Reports. 2012;14:245-50.
49. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-300.
50. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80.
51. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 2007;297:1675-82.
52. Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol. 2010;55:2727-35.
53. Lerch PG, Fortsch V, Hodler G, Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang. 1996;71:155-64.
54. Shaw JA, Bobik A, Murphy A, et al. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res. 2008;103:1084-91.
55. Patel S, Drew BG, Nakhla S, et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein antiinflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol. 2009;53:962-71.
56. Calkin AC, Drew BG, Ono A, et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation. 2009;120:2095-104.
57. CSL Limited. A single ascending dose study examining the safety and pharmacokinetic profile of reconstituted high density lipoprotein (CSL112) administered to patients. In: ClinicalTrials.gov. National Library of Medicine. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01499420. Accessed 11 Sept 2012.
58. Gualandri V, Franceschini G, Sirtori CR, et al. A-IMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083-97.
59. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I Milano mutant: the Limone sul Garda study. Circulation. 2001;103:1949-54.
60. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation. 1994;90:1935-41.
61. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein Edeficient mice. Circulation. 1998;97:780-5.
62. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein edeficient mice. Potential implications for acute plaque stabilization. Circulation. 2001;103:3047-50.
63. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging. J Am Coll Cardiol. 2008;51:1098-103.
64. Weibel GL, Alexander ET, Joshi MR, et al. Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux. Arterioscler Thromb Vasc Biol. 2007;27:2022-9.
65. Lebherz C, Sanmiguel J, Wilson JM, Rader DJ. Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007;6:15.
66. Parolini C, Chiesa G, Gong E, et al. Apolipoprotein A-I and the molecular variant apoA-I Milano: evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis. 2005;183:222-9.
67. Alexander ET, Weibel GL, Joshi MR, et al. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Arterioscler Thromb Vasc Biol. 2009;29:1496-501.
68. Sacks FM, Rudel LL, Conner A, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res. 2009;50:894-907.
69. Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580-9.
70. Nicholls SJ, Gordon A, Johansson J, et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statintreated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol. 2011;57:1111-9.
71. Resverlogix Corp; The Cleveland Clinic. The study of quantitative serial trends in lipids with apolipoprotein A-I stimulation (SUSTAIN). In: ClinicalTrials.gov. National Library of Medicine. 2012. http://www. clinicaltrials.gov/ct2/show/NCT01423188. Accessed 11 Sept 2012.
72. Resverlogix Corp; The Cleveland Clinic. ApoA-I synthesis stimulation and intravascular ultrasound for coronary atheroma regression evaluation (ASSURE I). In: ClinicalTrials.gov. National Library of Medicine. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01067820. Accessed 11 Sept 2012.
73. Rigamonti E, Helin L, Lestavel S, et al. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res. 2005;97:682-9.
74. Costet P, Luo Y, Wang N, Tall AR. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275:28240-5.
75. Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-62.
76. Briand F, Treguier M, Andre A, et al. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. J Lipid Res. 2010;51:763-70.
77. Giannarelli C, Cimmino G, Connolly TM, et al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: a magnetic resonance imaging study in a model of advanced atherosclerosis. Eur Heart J. 2012;33:264-73.
78. Grefhorst A, Elzinga BM, Voshol PJ, et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem. 2002;277:34182-90.
79. Lund EG, Peterson LB, Adams AD, et al. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alphaselective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol. 2006;71:453-63.
80. Zhang Y, Breevoort SR, Angdisen J, et al. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J Clin Invest. 2012; 122:1688-99.
81. van der Hoorn J, Linden D, Lindahl U, et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol. 2011;162:1553-63.
82. Yasuda T, Grillot D, Billheimer JT, et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2010;30:781-6.
83. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215-33.
84. Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570-3.
85. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121:2921-31.
86. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature. 2011;478:404-7.